Biocon receives approval for Insulin Glargine in Mexico through its partner PiSA Farmaceutica

The combined market for Insulin Glargine in Mexico is estimated to be in excess of $40 million

Biocon’s Insulin Glargine has been approved by COFEPRIS, the Mexican health authority, through its partner PiSA Farmaceutica (PiSA). Insulin Glargine will augment the affordable insulins therapy for diabetes management. ‘GALACTUS’ by PiSA is the first Insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012.

The company currently has marketing approvals in over 60 countries for rh-Insulin and in over 20 countries for Insulin Glargine.

Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon said, “We are committed to make global impact with our affordable insulins therapy. Our Insulin Glargine, will now enable access to a basal insulin which will further expand the diabetes management therapy for patients in Mexico.”

Biocon’s presence in Mexico, over the last eight years, has expanded the insulins market substantially by initiating many more patients onto insulin therapy. The increasing affordability of Insulin Glargine will now enable Biocon and PiSA to expand this reach further. The combined market for Insulin Glargine in Mexico is estimated to be in excess of $40 million.

EP News Bureau – Mumbai